Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Results: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ramucirumab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma has been completed w…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-14Clinical Trial Update: A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 3]
A Phase 3 trial comparing RPH-002 with Erbitux in unresectable metastatic or recurrent head and neck squamous cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers [Phase 2, Phase 3]
Phase 2/3 trial evaluating atezolizumab and/or bevacizumab with or without standard chemotherapy as second-line treatment for advanced head …
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment [Phase 3]
Phase 3 clinical trial evaluating adding cetuximab to pembrolizumab-based therapy for metastatic or recurrent head and neck squamous cell ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]
Phase 3 trial evaluating JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in locally advanced head and neck squamou…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC [Phase 2]
Phase 2 trial assessing induction and adjuvant camrelizumab with chemoradiation for locally advanced head and neck squamous cell carcinoma h…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck [Phase 2]
A Phase 2 trial evaluating the combination of atezolizumab and bevacizumab in recurrent or metastatic head and neck squamous cell carcinoma …
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]
Pfizer's Phase 1 trial of PF-08046037 alone or with sasanlimab in advanced cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors [Phase 1]
This first-in-human Phase 1 trial update reports ALX2004 for advanced or metastatic solid tumors and notes that the study is currently recru…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors [Phase 2]
This Phase 2 trial update evaluates the efficacy and safety of tisotumab vedotin in solid tumors. It includes colorectal cancer, non-small c…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment [Phase 3]
Phase 3 clinical trial evaluating the addition of cetuximab to pembrolizumab for recurrent or metastatic head and neck squamous cell carcino…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative …
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies [Phase 1]
Phase 1 trial evaluating CTX-471 as a monotherapy or in combination with pembrolizumab in patients who progressed after PD-1/PD-L1 inhibitor…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors [Phase 1]
Novartis' Phase 1 dose-finding trial of TNO155 in adults with advanced solid tumors has been terminated. No efficacy results are provided in…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer [Phase 2]
Phase 2 trial evaluating the combination of OSI-774 (gefitinib) with cisplatin and docetaxel in head and neck squamous cell carcinoma; resul…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas [Phase 1]
Phase 1 study evaluating CADI-05 in combination with pembrolizumab for surgically resectable locally advanced head and neck squamous cell ca…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer [Phase 1, Phase 2]
This is an update on a Phase 1/2 clinical trial evaluating the vaccine PDS0101 alone or in combination with pembrolizumab for locally advanc…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin [Phase 1]
Phase 1 trial evaluating the addition of M3814 (peposertib), a DNA-PK inhibitor, to radiation therapy in patients with advanced head and nec…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating BMS-986340 as monotherapy and in combination with nivolumab or docetaxel across several advanc…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 study of TransCon TLR7/8 agonist with or without pembrolizumab in patients with advanced or metastatic solid tumors has been ter…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors [Phase 1]
Phase 1 update reporting safety, pharmacokinetics, and preliminary efficacy data for AI-061 in advanced solid tumors across multiple indicat…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer [Phase 2]
Phase 2 study of pembrolizumab in combination with chemotherapy for head and neck squamous cell carcinoma is currently suspended.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC [Phase 2]
Phase 2 trial results of IO102-IO103 in combination with pembrolizumab as first-line therapy for metastatic non-small cell lung cancer, head…